$AMTX

Simon Timothy Alan sold $20K of AMTX

Simon Timothy Alan sold 10,000 shares of AEMETIS, INC (AMTX) at $2.05 on 2026-06-10.

Original reporting
SEC EDGAR · Simon Timothy Alan
Published Jun 11, 2026, 4:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 4:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AMTX
Neutral
medium confidence
Mentioned
$AMTX
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMTXNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity, but the disclosed transaction size is small and not accompanied by new operational/regulatory catalysts.

02

Market read

Fresh insider-sale disclosure may create minor sentiment pressure, but it is unlikely to materially change valuation absent additional company-specific news.

03

What to watch

The article provides only the sale size and post-transaction holdings; it does not show whether other insiders are buying, nor any concurrent operational news.

Relevance 3/10Novelty 6/10Timing: filed June 11; sale dated June 10

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Aemetis, Inc. (AMTX).

Company-level read

Ticker impact

$AMTXNeutralMedium confidence
Context

Director Simon Timothy Alan sold 10,000 AMTX shares in an open-market transaction for about $20.5K, per a fresh SEC Form 4 filing.

Expected impact

Likely limited, short-lived impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is primary-source and time-stamped, but the disclosed value (~$20.5K) is modest and does not include new company fundamentals or guidance.

Market effects

No sector read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Without a 10b5-1 plan, the sale could reflect diversification or personal liquidity needs rather than a bearish view on the business.

Key entities

  • Aemetis, Inc.

    Subject of the Form 4 insider transaction disclosure (AMTX).

  • Simon Timothy Alan

    Director who sold 10,000 shares in an open-market sale dated June 10, 2026.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMTXMedAI 8/10

Aemetis (AMTX) Q2 2026 Earnings Call Transcript

Aemetis (AMTX) reported Q2 2026 revenue of $62.7M, up 20% YoY, with operating income of $5.8M, reversing a prior-year loss. Growth was driven by ethanol and renewable natural gas segments. Adjusted EBITDA improved to $9.7M from -$5.8M. Management highlighted projects like mechanical vapor recompression and LCFS pathway approvals, but noted risks from uncertain emissions rates and feedstock constraints.

$AMTXMed

Aemetis (AMTX) Q2 2026 Earnings Call Transcript

Aemetis (AMTX) Q2 2026 earnings call said consolidated revenue rose 20% year over year, operating income improved by $16.4 million, and adjusted EBITDA increased by $15.5 million versus Q2 2025. The company cited CARB approval of 7 LCFS pathways and pending approvals for 6 digesters, plus ethanol projects including a $32 million annual cash flow MVR system. India biodiesel revenue was $2.5 million, with expected $17 million from new allocations.

$AMTXMed

Aemetis Q2 2026 Earnings: Financial Results, Revenue, and Segment Performance Highlights – Minichart

Aemetis reported Q2 2026 revenue of $62.7 million, up $10.5 million (20%) from Q2 2025, including $8.6 million from Section 45Z tax credits. Operating income improved by $16.4 million, net loss narrowed to $9.4 million, and adjusted EBITDA rose to $9.7 million. The company is pursuing refinancing and financing for its Keyes ethanol and Dairy RNG projects, and is considering an IPO for its India unit.

$AMTXMed

AEMETIS, INC (AMTX): Results of Operations and Financial Condition

AEMETIS, INC (AMTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 External Investor Relations Contact: Kirin Smith PCG Advisory Group (646) 863-6519 ksmith@pcgadvisory.com Company Investor Relations/ Media Contact: Todd Waltz (408) 213-0940 investors@aemetis.com Aemetis Reports Second Quarter 2026 Financial Results Revenue Growth o

$AMTXMed

Aemetis stock rises on India biodiesel supply deal

Aemetis Inc (NASDAQ:AMTX) shares rose 4.3% after its India unit, Universal Biofuels, secured about $17 million in biodiesel supply contracts. Over three months it will deliver more than 18 million liters to India’s three government-owned Oil Marketing Companies, supporting a policy to raise biodiesel blending to 5% by 2030. Additional orders are expected through 2026.